Cancer Guidelines Database

Access quality cancer guidelines from a single Canadian source

We've listed 56 guidelines under your selection of "Type of cancer". The most recent guidelines are first.

Locoregional Management of In-Transit Metastasis in Melanoma

Year: 2020
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult patients who were diagnosed with satellite lesions or in-transit metastases (ITM) from melanoma, with or without lymph node metastases. Available management options for these patients are discussed, such as the use of intralesional, topical, and regional therapies, and the recommended sequence of treatments is also addressed. Outcomes of interest include treatment response, disease recurrence, quality of life, toxicity, and survival.

Systemic Therapy for Melanoma: ASCO Guideline

Year: 2020
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for adult patients with melanoma, including those with cutaneous or non-cutaneous melanoma. The guideline examines adjuvant and neoadjuvant systemic therapy options for the treatment of these patients. Recommendations are separated based on disease stage, whether the melanoma is cutaneous or non-cutaneous, and whether or not the melanoma has been resected, is illegible for resection, or is unresectable/metastatic.

Primary Cutaneous Lymphomas, Version 2.2020

Year: 2020
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
A clinical practice guideline on the diagnosis, workup, and treatment of patients who have been diagnosed with or are suspected of having primary cutaneous B-cell lymphomas (PCBCLs). The guideline focuses on the three main types of PCBCLs: primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle-center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, leg type). Recommendations for treatment are provided based on lymphoma type and whether treatment is for initial, relapsed, or refractory disease.

Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: An ASTRO Clinical Practice Guideline

Year: 2020
AGREE II score: Available
Developer organization: American Society for Radiation Oncology
This is a clinical practice guideline for patients with basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC). The guideline examines the use of definitive and postoperative radiation therapy (RT) in these patients. Specific topics discussed include the appropriate indications for RT, preferred dose-fractionation schedules and radiation techniques, and the appropriate use of chemotherapy, biologic and immunotherapy agents before, during, or after RT.

Merkel Cell Carcinoma

Year: 2019
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult patients with Merkel cell carcinoma. The guideline examines the staging and work-up, treatment, follow-up, and management of recurrence in these patients. Treatment options discussed include surgery, radiation, chemotherapy, and immunotherapy. Clinical scenarios including clinical node-negative, clinical node-positive, and metastatic are considered, as is sentinel lymph node biopsy protocol.

Guidelines of Care for the Management of Primary Cutaneous Melanoma

Year: 2019
AGREE II score: Available
Developer organization: American Academy of Dermatology
This is a clinical practice guideline for patients with primary cutaneous melanoma. The guideline provides treatment recommendations for this patient population, including recommendations for surgical margins. Specific topics discussed include biopsy techniques for lesions that are clinically suggestive of melanoma, histopathologic interpretation of cutaneous melanoma, the use of laboratory, molecular, and imaging tests during initial work-up or follow-up, as well as the concept of staged excision.

Non-Melanoma

Year: 2019
AGREE II score: Unavailable
Developer organization: BC Cancer Agency
This is a clinical practice guideline for patients with non-melanoma skin cancer. The guideline discusses prevention, staging, treatment, and follow-up for these patients. Specific diseases discussed include basal cell carcinoma, squamous cell carcinoma, keratoacanthomas, Merkel cell tumours, Kaposi's sarcoma, extramammary Paget's disease (EMPD), and other non-melanoma skin cancers. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

Management of In-Transit Disease

Year: 2019
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients with melanoma who have developed in-transit metastases. The guideline discusses the treatment of in-transit disease, and provides recommendations on primary treatment, second-line treatment, adjuvant treatment, and radiation therapy. The primary outcomes of interest are progression-free survival and overall survival.

Systemic Adjuvant Therapy for Adult Patients at High Risk for Recurrent Melanoma

Year: 2019
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult patients with completely resected cutaneous or mucosal melanoma, who are at a high risk for recurrence. The guideline examines the use of adjuvant systemic therapy for the prevention of recurrence in these patients. Molecular testing is discussed, and different recommendations are made based on the presence or absence of BRAF V600E or V600K mutations.

Diagnosis and Treatment of Basal Cell Carcinoma: European Consensus-based Interdisciplinary Guidelines

Year: 2019
AGREE II score: Unavailable
Developer organization: European Dermatology Forum
This is a clinical practice guideline for patients with basal cell carcinoma (BCC). The guideline examines the diagnosis, treatment and follow-up of these patients. Treatment options discussed include surgical therapy, topical therapies, destructive therapies, photodynamic therapy, combined therapies, medical therapy and radiotherapy, and options are stratified by a proposed disease classification system that is based on the difficulty of successful treatment.

Melanoma

Year: 2019
AGREE II score: Unavailable
Developer organization: BC Cancer Agency
This is a clinical practice guideline for patients who have been diagnosed with melanoma, and those who are at high risk for melanoma. The guideline provides recommendations on prevention, screening of high risk individuals, diagnosis, staging, treatment, and follow-up. Treatment strategies explored include surgery, radiation therapy, and adjuvant chemotherapy, and recommendations are separated based on disease type. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

Diagnosis and Treatment of Merkel Cell Carcinoma in Specialized Dermatology Units: A Clinical Practice Guideline of the Spanish Academy of Dermatology and Venereology

Year: 2019
AGREE II score: Available
Developer organization: Spanish Academy of Dermatology and Venereology
This is a clinical practice guideline for adults with suspected or confirmed Merkel cell carcinoma (MCC). The guideline discusses the main techniques used for initial diagnosis and staging of MCC, as well as treatment options available for localized MCC. Specific topics addressed include the appropriateness of the AEIOU acronym (Asymptomatic, Expanding Rapidly, Immune suppression, Older than 50 years, UV-exposed site) for diagnosis, and the use of sentinel lymph node (SLN) biopsy during treatment.

Clinical Practice Guidelines for Keratinocyte Cancer

Year: 2019
AGREE II score: Available
Developer organization: Cancer Council Australia
This is a clinical practice guideline for adult patients with keratinocyte cancer (KC). The guideline examines the prevention, screening, diagnosis, treatment, and follow-up of these patients. Treatment options considered include surgery, radiotherapy, cryotherapy, topical treatments, and photodynamic therapy. Organ transplantation and conditions associated with immunosuppression are also discussed, as are systemic therapies for metastatic disease, the role of primary care, the economics of KC, and common concerns raised by patients. This guideline is wiki-based and is constantly updated as new evidence arises - this review pertains to the guideline as of January 15, 2020.

Mohs Micrographic Surgery

Year: 2019
AGREE II score: Available
Developer organization: Alberta Health Services
This is a clinical practice guideline for the surgical management of nonmelanoma skin cancer (NMSC) in adult patients. This guideline specifically focuses on the indications for Mohs micrographic surgery (MMS) to treat basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Clinical parameters such as location, size, borders, and site(s) of prior radiation therapy, as well as pathologic parameters such as growth pattern, degree of differentiation, and depth, are considered for risk-stratifying BCC and SCC patients.

Primary Cutaneous Lymphomas, Version 2.2019

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
A clinical practice guideline on the diagnosis, workup, and treatment of patients who have been diagnosed with or are suspected of having primary cutaneous B-cell lymphomas (PCBCLs). The guideline focuses on the three main types of PCBCLs: primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle-center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, leg type). Recommendations for treatment are provided based on lymphoma type and whether treatment is for initial, relapsed, or refractory disease.

Penile Cancer, Version 2.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of squamous cell carcinoma (SCC) of the penis. The guideline examines the diagnosis, treatment, and follow-up for patients with this form of cancer. Outcomes of interest include optimizing therapeutic efficacy and minimizing treatment-related morbidity.

British Association of Dermatologists and British Photodermatology Group Guidelines for Topical Photodynamic Therapy 2018

Year: 2018
AGREE II score: Available
Developer organization: British Association of Dermatologists
This is a clinical practice guideline for patients with nonmelanoma skin cancer, precancerous lesions, or infectious and inflammatory dermatoses. The guideline examines the use of topical photodynamic therapy (PDT) in these patients. Photosensitizing agents, photodynamic diagnosis, light sources and dosimetry, protocols for delivery of photodynamic therapy, and adverse effects are also discussed.

An Update on the Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma: Version 2.0

Year: 2018
AGREE II score: Available
Developer organization: Society for Immunotherapy of Cancer
This is a clinical practice guideline for patients with cutaneous melanoma. The guideline examines the immunotherapy options for the treatment of this patient population. Topics of interest include the different immunotherapy options for every stage of melanoma and special issues in tumour immunotherapy.

Patient Indications for Mohs Micrographic Surgery

Year: 2018
AGREE II score: Available
Developer organization: Cancer Care Ontario
This clinical practice guideline provides recommendations on the use of Mohs micrographic surgery (MMS) for adult patients diagnosed with skin cancer. MMS is compared to other surgical excision techniques, as well as other treatment modalities such as radiation. Guidance is provided on the indications and considerations for appropriate use of MMS, including disease stage, aesthetic outcomes, patient comorbidities, and patient preferences. Outcomes of interest include cure rate, recurrence rate, quality of life, and adverse events.

Merkel Cell Carcinoma, Version 1.2019

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with Merkel cell carcinoma. The guideline provides recommendations on diagnosis, workup, staging, radiation therapy, chemotherapy, follow-up, and recurrence. Specific recommendations are provided for the postoperative management of primary tumours, management of the draining nodal basin, and treatment of distant metastatic disease.

British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines for the Management of Primary Cutaneous Lymphomas 2018

Year: 2018
AGREE II score: Available
Developer organization: British Association of Dermatologists
This is a clinical practice guideline for the management of adult patients with primary cutaneous B-cell and T-cell lymphomas. This guideline does not include patients presenting with or found to have skin involvement as part of a systemic lymphoma. Treatment recommendations are organized by clinicopathological subtypes of lymphomas and are further stratified based on the stage of the disease. Economic and practical considerations of also discussed.

Primary Cutaneous B-Cell Lymphomas, Version 2.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
A clinical practice guideline on the diagnosis, work-up, and treatment of patients who have been diagnosed with or are suspected of having primary cutaneous B-cell lymphomas (PCBCLs). The guideline focuses on the three main types of PCBCLs: primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle-center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, leg type). Recommendations for treatment are provided based on lymphoma type and whether treatment is for initial, relapsed, or refractory disease.

Behavioral Counseling to Prevent Skin Cancer: US Preventive Services Task Force Recommendation Statement

Year: 2018
AGREE II score: Available
Developer organization: United States Preventive Services Task Force
This is a clinical practice guideline for the prevention and screening of skin cancer. Behavioural counselling recommendations are provided for young adults, adolescents, children, and parents of young children. Outcomes of interest include changes in sun protection behaviours, frequency of sunburn, and frequency of skin cancer.

Vulvar Cancer (Squamous Cell Carcinoma), Version 1.2018

Year: 2017
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for women with vulvar cancer, and particularly those with squamous cell carcinoma (SCC) of the vulva. The guideline examines diagnosis and workup, as well as primary treatment, adjuvant radiotherapy and chemotherapy, and surveillance of these patients. Treatment options are discussed for early-stage disease, locally advanced disease, and metastases beyond the pelvis.

Primary Excision Margins and Sentinel Lymph Node Biopsy in Cutaneous Melanoma

Year: 2017
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adults diagnosed non-metastatic cutaneous melanoma, located on the trunk, extremities, or head and neck. The guideline examines optimal excision margins and the use of sentinel lymph node biopsy (SLNB) in these patients. The recommendations are organized by location of melanoma on the body, and consider the thickness/depth of the melanoma. Outcomes of interest include recurrence rate, survival rate, morbidity, and rate of sentinel lymph node positivity.

Guidelines of Care for the Management of Cutaneous Squamous Cell Carcinoma

Year: 2017
AGREE II score: Available
Developer organization: American Academy of Dermatology
This is a clinical practice guideline for patients with cutaneous squamous cell carcinoma (cSCC). The guideline provides recommendations for the evaluation and management of patients with cSCC. Topics of interest include biopsy techniques and histopathologic assessment, tumour staging, surgical and non-surgical management, follow-up and prevention of recurrence, and management of advanced disease.

Squamous Cell Skin Cancer – Version 1.2017

Year: 2017
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for squamous cell skin cancer. Basal cell and squamous cell skin cancers, collectively known as non-melanoma skin cancers (NMSCs), are the most common cancer in the United States. The guideline provides recommendations related to clinical presentation and workup, local treatment, recurrence and metastasis, and follow-up. The guideline also provides a discussion about risk stratification and common risk factors including age, degree of differentiation, and site of prior radiotherapy.

Guidelines of Care for the Management of Basal Cell Carcinoma

Year: 2017
AGREE II score: Available
Developer organization: American Academy of Dermatology
This is a clinical practice guideline for adults who have been diagnosed with or are suspected of having basal cell carcinoma (BCC). The main focus of the guideline is on the most common approaches for the treatment of primary BCC, but it also includes recommendations on the treatment of recurrent tumours, appropriate biopsy techniques, staging, follow-up, and prevention of BCC.

British Association of Dermatologists’ Guidelines for the Care of Patients With Actinic Keratosis 2017

Year: 2017
AGREE II score: Available
Developer organization: British Association of Dermatologists
This is a clinical practice guideline for patients with actinic keratosis (AK). The guideline provides recommendations on treatment options such as topical therapies, cryosurgery, surgery, systemic therapy, photodynamic therapy, laser therapy, and combination treatment. Diagnosis and follow-up are also discussed.

Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update

Year: 2017
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for adults with melanoma. The guideline examines the use of sentinel lymph node (SLN) biopsy as a method for identifying nodal metastases, and provides recommendations on which patients should receive SLN biopsy based on the size and morphology of their melanoma. The guideline also discusses the appropriateness of completion lymph node dissection (CLND) as a method of treatment.

Merkel Cell Carcinoma – Version 1.2017

Year: 2017
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for merkel cell carcinoma. Merkel cell carcinoma is a rare, aggressive cutaneous tumor that combines the local recurrence rates of infiltrative non-melanoma skin cancer along with the regional and distant metastatic rates of thick melanoma. This guideline provides recommendations for diagnosis and workup, staging, treatment, follow-up and recurrence. Treatment recommendations include surgery, sentinel lymph node biopsy, radiation therapy, and chemotherapy as possible options.

Cutaneous Melanoma: A National Clinical Guideline

Year: 2017
AGREE II score: Available
Developer organization: Scottish Intercollegiate Guidelines Network
This is a clinical practice guideline for patients with cutaneous melanoma. The guideline examines the care of these patients throughout the cancer care continuum, including prevention and surveillance, diagnosis and prognosis, surgical management and staging, further investigations and non-surgical staging, adjuvant treatment of stage 2 and 3 melanoma, follow up of patients with stage 1, 2 and 3 melanoma, and management of advanced (unresectable stage 4 or 5) melanoma.

French Updated Recommendations in Stage I to III Melanoma Treatment and Management

Year: 2017
AGREE II score: Unavailable
Developer organization: French Dermatological Society
This is a clinical practice guideline for the management of stage I to III melanoma in adult patients. The guideline discusses classification, resection margins, sentinel node biopsy, adjuvant treatments, initial work-up, follow-up, and the role of molecular biology tests. The guideline also compares the recommendations provided by other European guidelines and addresses any disparities in recommendations.

Basal Cell Skin Cancer – Version 1.2017

Year: 2017
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for basal cell skin cancer. The guideline considers clinical presentation and workup, local treatment, recurrence and metastasis, and follow-up. The guideline also includes a discussion about risk stratification and explores different risk factors for basal cell skin cancer including location and size, age, and site of prior radiotherapy.

Surgical Management of Patients With Lymph Node Metastases from Cutaneous Melanoma of the Trunk or Extremities

Year: 2016
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult patients with cutaneous melanoma of the trunk or extremities. The guideline examines the optimal surgical management of patients with positive sentinel lymph nodes (SLNs) and biopsy-proven clinically palpable or biopsy-proven radiologically detected lymph nodes from cutaneous melanoma originating in the trunk or extremities. Outcomes of interest include local and regional recurrence, distant recurrence, overall survival (OS), and disease-free survival (DFS).

Sentinel Node Biopsy in Primary Cutaneous Melanoma

Year: 2016
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This clinical practice guideline reviews the use of sentinel node biopsy (SLNB) as a diagnostic tool for adult patients with malignant melanoma. Topics of discussion include indications and contraindications of SLNB, pathological examination of the sentinel nodes, and indications for therapeutic node dissection and recommended extent of dissection. The use of ultrasound-guided fine-needle aspiration is also discussed. Outcomes of interest include test sensitivity, specificity, and positive and negative predictive value, as well as rate of nodal recurrence and survival.

Consensus Recommendations for Management of Malignant Melanoma

Year: 2016
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the management of malignant melanoma. Topics of interest include acceptable time intervals from referral to surgical management, which patients should be candidates for sentinel lymph node biopsy, and acceptable surgical margins.

Screening for Skin Cancer US Preventive Services Task Force Recommendation Statement

Year: 2016
AGREE II score: Available
Developer organization: United States Preventive Services Task Force
This is a clinical practice guideline for the screening of skin cancer in asymptomatic adults. The recommendations do not apply to patients with suspicious skin lesions, family history of skin cancer, or personal history of pre-malignant or malignant skin lesions. Outcomes of interest include reductions in morbidity and mortality from skin cancers.

The Use of Adjuvant Radiation Therapy for Curatively Resected Melanoma

Year: 2016
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for patients with stage 1-3 cutaneous melanoma who have received curative resection. The guideline examines the appropriateness of adjuvant radiation therapy (RT) for these patients, narrowing the focus on those patients with primary melanoma, in-transit primary melanoma, recurrent melanoma, and those at high risk for regional recurrence of melanoma. The guideline also considers whether equivalent disease control is provided with a standard fractionation schedule and a hypofractionated schedule. Outcomes of interest include control rate, survival rate and adverse event rates.

Fertility Drugs and Cancer: A Guideline

Year: 2016
AGREE II score: Unavailable
Developer organization: American Society for Reproductive Medicine
This clinical practice guideline examines the impact of fertility drugs on the risk of cancer in women. The guideline looks at the association between use of fertility drugs and increased risk of developing invasive ovarian, breast, endometrial, colon and thyroid cancers as well as non-Hodgkin lymphoma and malignant melanoma. The association between fertility drugs and borderline ovarian tumours is also examined.

Clinical Practice Guidelines for the Diagnosis and Management of Melanoma

Year: 2016
AGREE II score: Available
Developer organization: Cancer Council Australia
This is a clinical practice guideline for the diagnosis and management of melanoma. The purpose of these guidelines is to achieve early diagnosis whenever possible, make doctors and patients aware of the most effective treatment options, and minimize the financial burden on the health system by documenting investigations and therapies that are inappropriate. Topics discussed include: features of melanoma, biopsy, sentinel node biopsy, and excision margins.

Non-Melanoma Skin Cancer in Canada Chapter 2: Primary Prevention of Non-Melanoma Skin Cancer

Year: 2015
AGREE II score: Unavailable
Developer organization: Canadian Non-melanoma Skin Cancer Guidelines Committee
A clinical practice guideline for the primary prevention of non-melanoma skin cancer, including basal and squamous cell carcinoma. The guideline examines modifiable risk factors for developing skin cancer, focusing primarily on photoprotection at an individual and public health level. Outcomes of interest include reduced actinic keratoses through daily sunscreen use and clarification of labelling standards. This guideline is Chapter 2 of 5 of the Non-melanoma Skin Cancer in Canada guideline series.

Melanoma: Assessment and Management

Year: 2015
AGREE II score: Available
Developer organization: National Institute for Health and Care Excellence
This clinical practice guideline is for patients diagnosed with or suspected of having melanoma. The guideline provides recommendations on diagnostic assessment, staging, and management. Follow-up care is also discussed, including topics such as management of suboptimal Vitamin D levels and concurrent drug therapies. Outcomes of interest include survival (overall, disease free, melanoma specific), and adverse events (acute toxicity, wound/sensory complications).

Non-Melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses

Year: 2015
AGREE II score: Unavailable
Developer organization: Canadian Non-melanoma Skin Cancer Guidelines Committee
A clinical practice guideline for the treatment of actinic keratosis and cheilitis as precursors to invasive squamous cell carcinomas. The guideline examines treatment options including surgical and topical removal, and considers the use of combined modalities. There is also specific information for the monitoring and treatment of long-term immunosuppressed patients. Outcomes of interest include improved cosmetic results through the use of topical methods. This guideline is Chapter 3 of 5 of the Non-melanoma Skin Cancer in Canada guideline series.

Dermatofibrosarcoma Protuberans, Version 1.2016

Year: 2015
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for dermatofibrosarcoma protuberans (DFSP). The NCCN Non-Melanoma Skin Cancer Panel has developed these guidelines outlining the treatment of DFSP to supplement their guidelines for basal cell and squamous cell skin cancers and merkel cell carcinoma. Topic areas discussed in this guideline as they relate to DFSP include: biopsy, surgery, chemotherapy, and radiotherapy.

Management of Cutaneous Squamous Cell Carcinoma in Patients With Epidermolysis Bullosa: Best Clinical Practice Guidelines

Year: 2015
AGREE II score: Unavailable
Developer organization: British Association of Dermatologists
This is a clinical practice guideline for patients with epidermolysis bullosa. The guideline provides recommendations for the diagnosis, staging, and management of cutaneous squamous cell carcinoma (SCC) in these patients. Specific topics discussed include surveillance and diagnosis, tumour evaluation and staging, surgical treatment, nonsurgical treatment, the use of prosthetics, and end-of-life care.

Guidelines of the Brazilian Dermatology Society for Diagnosis, Treatment and Follow Up of Primary Cutaneous Melanoma – Part I

Year: 2015
AGREE II score: Unavailable
Developer organization: Brazilian Dermatology Society
A clinical practice guideline for patients with primary cutaneous melanoma. The guideline examines the use of dermoscopy for diagnosis, and treatment including appropriate surgical margins. Outcomes of interest include prognostic improvement, aesthetic impairment, and cure rates.

Oncogenetic Testing, Diagnosis and Follow-up in Birt-Hogg-Dubé Syndrome, Familial Atypical Multiple Mole Melanoma Syndrome and Neurofibromatosis 1 and 2

Year: 2015
AGREE II score: Available
Developer organization: Belgian Health Care Knowledge Centre
This is a clinical practice guideline for patients at risk of Birt-Hogge-Dubé Syndrome, the familial atypical multiple mole melanoma syndrome and neurofibromatosis 1&2, either based on clinical suspicion or family history. The guideline reviews indications for genetic testing, clinical utility of specific genetic tests, and follow-up depending on test results and family history. Impact of genetic counselling and test on patient behaviour and distress levels is also reviewed.

Indication Guidelines for Mohs Micrographic Surgery in Skin Tumors

Year: 2015
AGREE II score: Unavailable
Developer organization: Brazilian Society of Dermatology
This is a clinical practice guideline for patients with skin tumours. The guideline examines the indications for Mohs micrographic surgery in these patients. Indications related to recurrence, histology, size, definition of tumour margins, and tumour location are discussed. The use of Mohs micrographic surgery for treating different types of skin tumours is compared to conventional surgery in the appropriate situations.

Follow-up of Patients with Cutaneous Melanoma who were Treated with Curative Intent

Year: 2015
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for patients with cutaneous melanoma after treatment with curative intent. The guideline provides recommendations on follow-up schedules, involving appropriate evaluations and timing for early detection of local-regional recurrence, distant metastases, and new primary melanomas. Diagnostic imaging modalities such as ultrasound (US), computed tomography (CT), positron emission tomography (PET), and PET/CT, laboratory tests such as LDH and S100B, skin self-examinations, and dermoscopy/dermatoscopy are discussed.

Non-Melanoma Skin Cancer in Canada Chapter 5: Management of Squamous Cell Carcinoma

Year: 2015
AGREE II score: Unavailable
Developer organization: Canadian Non-melanoma Skin Cancer Guidelines Committee
A clinical practice guideline for the staging and treatment of squamous cell carcinoma. The guideline examines treatment options, primarily surgical excision, and provides guidelines for immunocompromised and high-risk patients. Outcomes of interest include improved tissue sparing through Mohs micrographic surgery, and improved understandings of surgical margins. This guideline is Chapter 5 of 5 of the Non-melanoma Skin Cancer in Canada guideline series.

Non-Melanoma Skin Cancer in Canada Chapter 4: Management of Basal Cell Carcinoma

Year: 2015
AGREE II score: Unavailable
Developer organization: Canadian Non-melanoma Skin Cancer Guidelines Committee
A clinical practice guide for the staging and treatment of basal cell carcinoma. The guideline examines numerous treatment options, including cryosurgery, topical, and photodynamic approaches. Outcomes of interest include reduced recurrence rates with surgical excision and Mohs micrographic surgery. This guideline is Chapter 4 of 5 of the Non-melanoma Skin Cancer in Canada guideline series.

Systemic Therapy for Unresectable Stage III or Metastatic Cutaneous Melanoma

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adults over the age of 18 years with unresectable stage III and stage IV cutaneous melanoma, without involvement of the central nervous system (CNS). The guideline reviews the use of BRAF biomarker testing, and provides recommendations for first- and second-line systemic therapy options. BRAF Inhibitors, MEK inhibitors, immune checkpoint Inhibitors, other biological agents (e.g. imatinib and bevacizumab), and chemotherapy agents are reviewed.

Merkel Cell Carcinoma

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adults over the age of 18 years with Merkel cell carcinoma of the skin. The guideline provides recommendations on staging and work-up, treatment options including surgery, radiation, and chemotherapy, and follow-up care. The guideline also provides recommendations on management of recurrences, and reviews sentinel lymph node biopsy protocol.

Suspected Cancer: Recognition and Referral

Year: 2015
AGREE II score: Available
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline for patients of all age groups suspected of having cancers including lung and pleural, upper gastro-intestinal, lower gastrointestinal, breast, gynecological, urological, skin, head and neck, brain and central nervous system, haematological, sarcomas, and childhood cancers. Recommendations are provided on recognition and referral or investigations of cancer in primary care. Outcomes of interest include quality of life, sensitivity and specificity of diagnostic tests and signs/symptoms, positive and negative predictive values of diagnostic tests and signs/symptoms, and cost effectiveness.